BAY 3713372 / Suzhou Puhe Pharma, Bayer - LARVOL DELTA

A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors (clinicaltrials.gov) - P1/2 | N=370 | Recruiting | Sponsor: Bayer | Phase classification: P1 ➔ P1/2 | N=70 ➔ 370

Enrollment change • First-in-human • Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Bayer

New P1 trial • Oncology • Solid Tumor

Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor (Bayer Press Release) - "Bayer and Suzhou Puhe BioPharma...announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase I first-in-human dose escalation study investigating MTA-cooperative PRMT5 inhibitor under the development name BAY 3713372 for the treatment of MTAP-deleted solid tumors."

Licensing / partnership • Trial status